Nkarta (NKTX) Competitors

Nkarta (NASDAQ:NKTX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Do analysts prefer NKTX or AMLX?

Nkarta currently has a consensus target price of $14.67, suggesting a potential upside of 730.97%. Amylyx Pharmaceuticals has a consensus target price of $9.83, suggesting a potential upside of 83.46%. Given Nkarta's higher probable upside, equities research analysts clearly believe Nkarta is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13
Amylyx Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.13

Which has preferable earnings & valuation, NKTX or AMLX?

Amylyx Pharmaceuticals has lower revenue, but higher earnings than Nkarta. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$117.50M	-$1.51	-1.17
Amylyx Pharmaceuticals	-$1.27M	-375.63	$49.27M	-$3.11	-1.72

Which has more volatility & risk, NKTX or AMLX?

Nkarta has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500.

Is NKTX or AMLX more profitable?

Nkarta's return on equity of -27.13% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-27.13%	-21.67%
Amylyx Pharmaceuticals	N/A	-36.97%	-29.61%

Does the MarketBeat Community believe in NKTX or AMLX?

Nkarta received 26 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 76.47% of users gave Nkarta an outperform vote while only 69.64% of users gave Amylyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Nkarta	Outperform Votes 65 76.47%	Underperform Votes 20 23.53%
Amylyx Pharmaceuticals	Outperform Votes 39 69.64%	Underperform Votes 17 30.36%

Does the media refer more to NKTX or AMLX?

In the previous week, Nkarta had 14 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 22 mentions for Nkarta and 8 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 0.82 beat Nkarta's score of 0.28 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nkarta	7 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amylyx Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in NKTX or AMLX?

80.5% of Nkarta shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 8.7% of Nkarta shares are owned by company insiders. Comparatively, 11.7% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Nkarta beats Amylyx Pharmaceuticals on 10 of the 14 factors compared between the two stocks.